What is the impact of type 2 diabetes mellitus and increased glycaemia on cardiovascular risk?
Authors:
J. Perušičová
Authors‘ workplace:
Interní klinika UK 2. LF a FN Motol
Published in:
Kardiol Rev Int Med 2009, 11(3): 117-121
Category:
Nontraditional risk factors cardiovascular disease
Overview
Hyperglycaemia is an independent risk factor for cardiovascular diseases. The very close association between type 2 diabetes mellitus and cardiovascular diseases has repeatedly been confirmed and led to a view that „diabetes is a cardiovascular disease“. More than 75% of patients with type 2 diabetes die from cardiovascular complications. Intensive hyperglycaemia treatment could play a role in preventing (or at least delaying) progression of macroangiopathic complications. The main mechanisms of proatherogenic effects of hyperglycaemia are as follows: increased formation of free radicals, protein glycation and production of glycation end‑products. The risk of elevated blood glucose levels begins at the stage of pre‑diabetes and is mainly related to increased postprandial glycaemia levels.
Keywords:
cardiabetes – dysglycaemia – hyperglycaemia
Sources
1. Juutilainen A, Lehto S, Rönnemaa T et al. Type 2 diabetes as a „coronary heart disease equivalent“: an 18-year prospective population‑based srudy in Finnish subjects. Diabetes Care 2005; 28: 2901–2907.
2. Perušičová J. Co je nového na cestě od diabezity po kardiabetes. Praha: GEUM 2006: 5–186.
3. Perušičová J, Češka R (eds). Kardiabetes: Kardiovaskulární choroby a diabetes mellitus. Brno: Facta Medica 2009.
4. Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298: 765–775.
5. Stevens RJ, Kothari V, Adler AI et al. United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101: 671–679.
6. Guha A, Harmancey R, Taegtmeyer H. Nonischemic heart failure in diabetes mellitus. Curr Opin Cardiol 2008; 23: 241–248.
7. Whiting PH, Kalansooriya A, Holbrook I et al. The relationship between chronic glycaemic control and oxidative stress in type 2 diabetes mellitus. Br J Biomed Sci 2008; 65: 71–74.
8. Gleissner CA, Galkina E, Nadler JL et al. Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today Dis Mech 2007; 4: 131–140.
9. Cho E, Rimm EB, Stampfer MJ et al. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 2002; 40: 954–960.
10. Nwose EU, Richards RS, Kerr RG et al. Oxidative damage indices for the assessment of subclinical diabetic macrovascular complications. Br J Biomed Sci 2008; 65: 136–141.
11. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335–342.
12. Borradaile NM, Schaffer JE. Lipotoxicity in the heart. Curr Hypertens Rep 2005; 7: 412–417.
13. Buse JB, Ginsberg HN, Bakris GL et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114–126.
14. Eurich DT, McAlister FA, Blackburn DF et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335: 497–507.
15. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–591.
16. Lee CD, Folsom AR, Pankow JS et al. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004; 109: 855–860.
17. Mulnier HE, Seaman HE, Raleigh VS et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologie 2008; 51: 1639–1645.
18. Nathan DM, Buse JB, Davidson B et al. Medical management of hyprglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjusment of therapy: A consensus statement from the American Diabetes Assotiation and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17–30.
19. Schroeder SA, Tayek JA, Gæde P et al. Multifactorial Intervention and Mortality in Type 2. Diabetes. N Engl J Med 2008; 358: 2292–2293.
20. Taskinen MR. Diabetic dyslipidemia. Atheroscler Suppl 2002; 3: 47–51.
21. Damm P. Future risk of diabetes in mother and child after gestational diabetes mellitus. Int J Gynaecol Obstet 2009; 104 (Suppl 1): S25–S26.
22. Cavalot F, Petrelli A, Traversa M et al. Postprandial Blood Glucose Is a Stronger Predictor of Cardiovascular Events Than Fasting Blood Glucose in Type 2 Diabetes Mellitus, Particularly in Women: Lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006; 91: 813–819.
23. Triggle CR. The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Timely Top Med Cardiovasc Dis 2008; 12: E3.
24. Bolli GB. Glucose Variability and Complications. Diabetes Care 2006; 29: 1707–1709.
25. Ceriello A, Esposito K, Piconi L et al. Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients. Diabetes 2008; 57: 1349–1354.
26. Eldin WS, Emara M, Shoker A. Prediabetes: a must to recognise disease state. Int J Clin Pract 2008; 62: 642–648.
27. Sen K, Mukherjee AK, Dharchowdhury L et al. A study to find out the proportion of prediabetes in patients with acute coronary syndrome in a medical college of Kolkata. J Indian Med Assoc 2008; 106: 776–778.
28. Dagogo-Jack S, Askari H, Tykodi G. Glucoregulatory Physiology in Subjects with Low-Normal, High‑Normal, or Impaired Fasting Glucose. Clin Endocrinol Metab 2009; 94: 2031–2036.
29. Charfen MA, Ipp E, Kaji AH et al. Detection of Undiagnosed Diabetes and Prediabetic States in High‑risk Emergency Department Patients. Acad Emerg Med 2009; 16: 1–9.
30. Mendoza A, Kim YN, Chernoff A. Hypoglycemia in hospitalized adult patients without diabetes. Endocr Pract 2005; 11: 91–96.
31. Pladziewicz DS, Nesto RW. Hypoglycemia‑induced silent myocardial ischemia. Am J Cardiol 1989; 63: 1531–1532.
32. Wei M, Gibbons LW, Mitchell TL et al. Low fasting plasma glucose level as a predictor of cardiovascular disease and all‑cause mortality. Circulation 2000; 101: 2047–2052.
33. Svensson AM, McGuire DK, Abrahamsson P et al. Association between hyper‑ and hypoglycaemia and 2 year all‑cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005; 26: 1255–1261.
34. Eschwege E, Richard JL, Thibult N et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res Suppl 1985; 15: 41–46.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2009 Issue 3
Most read in this issue
- ECG monitoring with Holter monitor
- Current opinions about the role of mild hyperhomocysteinaemia as a risk factor of cardiovascular diseases
- Uric acid and cardiorenal risk
- HRT and cardi ovascular risk